Goldfinch Bio, a biotechnology company focused on discovering and developing precision medicines for the treatment of genetically-driven kidney diseases, today announced the presentation of preclinical data enabling the advancement of innovative approaches to the treatment of kidney disease. These data, which were presented at the International Society of Nephrology (ISN) World Congress 2019, held April 12-15 in Melbourne, Australia include:
- Transient receptor potential canonical 5 (TRPC5) inhibition with GFB-887 provides protection against podocyte injury and proteinuria in models of focal segmental glomerulosclerosis (FSGS) treatment-resistant minimal change disease (TR-MCD) and diabetic nephropathy.
- The integration of longitudinal clinical data with genetic and transcriptomic data enables the Goldfinch Kidney Genome Atlas„¢ (KGA) to uncover novel targets related to kidney disease progression.
- The development of podocyte cellular models and organoids facilitate assessment of kidney disease mechanisms and treatment response.
The comprehensive body of data presented by the Goldfinch team at the ISN World Congress 2019 clearly demonstrate the significant advances that Goldfinch Bio is making towards the development of novel therapeutics for kidney disease, said Anthony Johnson, M.D., President and Chief Executive Officer of Goldfinch Bio. The Goldfinch KGA, which is the backbone of our product engine, has enabled the discovery of genetic variants associated with kidney disease. These genetic variants, combined with the integration of clinical and transcriptomic data, advance our understanding of the molecular causes of kidney diseases and drive our development pipeline. We remain on track to initiate clinical studies with GFB-887, our selective, small molecule TRPC5 inhibitor, in the first half of 2019.
In a poster titled ˜GFB-887, a small molecule inhibitor of TRPC5, protects against podocyte injury and attenuates proteinuria in models of FSGS, Goldfinch Bio researchers describe the identification of potent and selective novel small molecule inhibitors of TRPC5, including the development candidate, GFB-887, for the treatment of proteinuria in FSGS, TR-MCD and diabetic kidney disease (DKD).
In a poster titled ˜The Kidney Genome Atlas: a comprehensive whole genome and transcriptome landscape of proteinuric kidney diseases, Goldfinch Bio researchers describe the functionality of the KGA and its role in advancing the understanding of the molecular mechanisms of kidney diseases at a whole genome and transcriptome scale.
In a poster titled, ˜Comparative transcriptomic analysis of cultured podocytes and human kidney organoids at single cell-resolution, Goldfinch Bio researchers describe the advancement of a model of mature podocytes with the potential to assess both mechanisms of human kidney disease and responses to treatment.
About Goldfinch Bio Goldfinch Bio is a biotechnology company that is singularly focused on discovering and developing precision therapies for patients with kidney diseases. Just as the goldfinch has long been a symbol of healing and renewal and was a prominent figure of the Renaissance, Goldfinch Bio is leading a new age of therapeutic discovery to transform the treatment paradigm for patients with kidney diseases. Goldfinch was launched in 2016 by Third Rock Ventures, and is headquartered in Cambridge, Mass. For more information, please visit www.goldfinchbio.com.
The Yates Network
Gina Nugent 617-460-3579